Summary: Cigna Healthcare modified its coverage policy for Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF-EMF) therapy — marketed primarily under the Therabionic device — effective April 16, 2026. Here's what billing teams need to know before claims go out the door.
Cigna Healthcare's AM RF-EMF therapy coverage policy (policy 0581) covers the Therabionic device, a noninvasive treatment that delivers tumor-specific radiofrequency signals. This policy modification signals Cigna's updated position on whether AM RF-EMF therapy meets medical necessity thresholds for covered indications. The policy does not list specific CPT or HCPCS codes in the available data — more on that below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF-EMF) Therapy |
| Policy Code | 0581 |
| Change Type | Modified |
| Effective Date | 2026-04-16 |
| Impact Level | Medium — affects oncology and integrative medicine billing teams submitting AM RF-EMF claims |
| Specialties Affected | Oncology, integrative medicine, radiation therapy |
| Key Action | Review all pending and queued AM RF-EMF claims before April 16, 2026 and confirm documentation meets Cigna's updated medical necessity criteria |
Cigna AM RF-EMF Therapy Coverage Criteria and Medical Necessity Requirements 2026
The core question with this policy is whether Cigna treats AM RF-EMF therapy as a covered service or as experimental and investigational. Historically, Cigna's 0581 policy has classified the Therabionic device as not medically necessary for any indication. That classification drives denials, so understanding exactly what — if anything — changed in this modification is critical before your next billing cycle.
The Therabionic device delivers amplitude-modulated radiofrequency electromagnetic fields at tumor-specific frequencies. Proponents argue it can reduce tumor burden, particularly in hepatocellular carcinoma. The clinical evidence base, however, remains limited to small trials and case series, which is the primary reason payers including Cigna have historically withheld coverage.
Because the full updated policy text is not available in this data pull, billing teams should access the current policy directly at Cigna's coverage position criteria page for 0581 before the effective date of April 16, 2026. Do not rely on the previous policy version to determine coverage status.
For prior authorization purposes: if Cigna's updated policy adds any covered indications, prior authorization is almost certainly required. Cigna requires prior auth on nearly all emerging technology and oncology device services. Assume you need it until the policy text confirms otherwise.
This is the same pattern Cigna used when it modified its coverage policy for other noninvasive tumor treatment technologies — a modification can mean added coverage, tightened criteria, or clarified exclusions. Any of those changes will affect your reimbursement rate and your denial rate directly.
Cigna AM RF-EMF Therapy Exclusions and Non-Covered Indications
Based on Cigna's prior position on AM RF-EMF therapy under policy 0581, this treatment has been classified as experimental and investigational across all indications. A "modified" designation does not automatically mean coverage was added. It means something in the policy criteria changed — that could be language tightening, evidence standard updates, or new exclusion language.
The real issue here is that billing teams often assume a policy modification means expanded coverage. That's not always true. Cigna modifies policies to sharpen exclusions just as often as it adds covered indications.
Until you read the April 16, 2026 version of policy 0581 in full, treat AM RF-EMF therapy as non-covered under Cigna for all indications. Submit claims only after you've confirmed the updated coverage position, documented medical necessity clearly, and obtained prior authorization if required.
If your practice has patients using the Therabionic device under a Cigna plan, talk to your compliance officer before the effective date. The financial exposure from claim denial on oncology services is high, and a few denied claims in this category can distort your payer mix revenue significantly.
Coverage Indications at a Glance
The available policy data does not include indication-level coverage criteria from the updated Cigna 0581 policy. The table below reflects Cigna's known historical position on AM RF-EMF therapy indications. Verify against the April 16, 2026 policy document before billing.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Hepatocellular carcinoma (HCC) | Experimental / Not Covered (historical) | Not specified in policy data | Most studied indication for Therabionic; verify updated status |
| Breast cancer | Experimental / Not Covered (historical) | Not specified in policy data | Limited clinical trial data; verify updated status |
| Prostate cancer | Experimental / Not Covered (historical) | Not specified in policy data | Verify updated status against April 16 policy version |
| Other solid tumors | Experimental / Not Covered (historical) | Not specified in policy data | Blanket exclusion historically applied; verify updated status |
Cigna AM RF-EMF Therapy Billing Guidelines and Action Items 2026
Here's what your billing team should do right now, before April 16, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the updated policy document directly. Go to Cigna's coverage position criteria page for policy 0581 at the source URL above. Read the April 16, 2026 version, not the cached or previous version. Every action item below depends on what that document says. |
| 2 | Audit any queued AM RF-EMF claims before April 16. If you have claims staged for AM RF-EMF therapy services that haven't been submitted, hold them. Submit only after you've confirmed the updated coverage criteria. A claim submitted under the old policy terms and denied under the new ones is a recoverable problem — but it creates rework. |
| 3 | Check prior authorization requirements for every Cigna plan in your payer mix. Cigna prior authorization requirements vary by plan type. Commercial, Exchange, and Medicare Advantage plans under Cigna can have different rules. Confirm prior auth is on file before submitting any AM RF-EMF claim. |
| 4 | Update your denial tracking for AM RF-EMF services. If you've received claim denial notices on Therabionic or AM RF-EMF services in the past 90 days, flag those accounts. If the April 16 modification adds coverage, some of those denials may be eligible for reconsideration. Check the denial date against the effective date and document the timeline. |
| 5 | Review your charge capture if you're using unlisted codes. Because no specific CPT or HCPCS codes are assigned to AM RF-EMF therapy in the available policy data, billing teams often fall back on unlisted procedure codes. Unlisted codes require detailed documentation and are scrutinized heavily in medical necessity reviews. Make sure your supporting documentation for any unlisted code submission is complete, current, and references the specific Therabionic treatment protocol. |
| 6 | Brief your clinical team on documentation requirements. Cigna's medical necessity reviews for experimental technology denials are documentation-intensive. Your oncologists or treating physicians need to understand what Cigna's reviewers are looking for. If the updated policy adds covered indications with specific clinical criteria — diagnosis stage, prior treatment failure, performance status requirements — those criteria must appear in the medical record before you bill. |
| 7 | Loop in your billing consultant or compliance officer if you're unsure. AM RF-EMF therapy sits in a gray zone for most commercial payers. If your practice generates meaningful revenue from Therabionic treatments and you're not certain how this modification changes your exposure, don't guess. Talk to your compliance officer before the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for AM RF-EMF Therapy Under Cigna Policy 0581
The Cigna 0581 policy data available for this modification does not include specific CPT, HCPCS Level II, or ICD-10-CM codes. This is common for emerging technology policies, where no dedicated procedure code exists and billing typically uses unlisted codes.
What this means for your billing team:
Cigna AM RF-EMF therapy billing without a specific CPT or HCPCS code means you're working with unlisted procedure codes. Those codes do not auto-adjudicate. They go to manual medical necessity review every time.
This increases your claim cycle time and your denial exposure simultaneously. Every submission needs to carry complete documentation — treatment rationale, clinical evidence cited, prior treatment history, and the specific Therabionic protocol used.
If a CPT or HCPCS code is added to policy 0581 in the April 16, 2026 version, update your charge master immediately. Don't let the team continue billing unlisted codes if a specific code now applies — that's a reimbursement leak and a compliance risk at the same time.
Check back at PayerPolicy.org once the full updated policy text is confirmed. We will update this post with specific codes as soon as the April 16, 2026 policy version is available and coded.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.